Cel-Sci Corp Dossier
Qualitative Analysis
Business overview
CEL-SCI Corporation (NYSE American: CVM) is a late clinical-stage biotechnology company focused on researching, developing, and manufacturing investigational immunotherapy products designed to enhance the body's natural immune system to fight cancer and other diseases. The company's lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), a neoadjuvant immunotherapy designed to be administered immediately after diagnosis and before surgery, radiation, or chemotherapy. Multikine has received Orphan Drug designation from the U.S. FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. Additionally, CEL-SCI is developing its Ligand Epitope Antigen Presentation System (LEAPS) technology, which includes vaccine candidates like CEL-4000 for the potential treatment of rheumatoid arthritis.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead investigational immunotherapy Multikine through parallel regulatory pathways: a 212-patient Confirmatory Registration Study in the U.S. and market entry in Saudi Arabia via a strategic partnership.
Expected impact: Aims to secure accelerated FDA approval based on pre-surgical tumor responses and establish early commercial revenue streams in the Middle East.
Securing operational runway through public equity offerings and cost-reduction measures in R&D and G&A expenses.
Expected impact: Provides narrow financial runway to initiate the confirmatory registration study and address going concern uncertainties.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides a pathway to potential early commercialization and revenue generation for Multikine in Saudi Arabia and potentially other Gulf Cooperation Council (GCC) countries.
Terms: Includes a 50%/50% net revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation.